Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07686068 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by VelaVigo Bio.
- Not yet
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
NCT07686068 is a Phase 1 study that has not yet begun recruiting, run by VelaVigo Bio. The registered enrollment target is 260 participants.
The verdict
NCT07686068, a Phase 1 study, has not yet begun recruiting, sponsored by VelaVigo Bio.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.
Interventions
- DRUG VBC106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2026-08-18 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07686068
The ClinicalTrials.gov registry entry for NCT07686068 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VelaVigo Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VBC106 is the first listed.
NCT07686068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07686068 about?
NCT07686068 is a clinical study titled "First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors". This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to fu...
What is the current status of trial NCT07686068?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2026-08-18. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07686068?
The interventions under investigation include: VBC106 (DRUG).
Who is sponsoring clinical trial NCT07686068?
This trial is sponsored by VelaVigo Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.